Do you think in aptamers?
Think in AptusBiotech

Do you think in aptamers? Think in AptusBiotech


Aptus Biotech is a biotech start-up SME founded in 2010 from a collaboration agreement with the Ramon y Cajal Hospital Foundation (FIBio-HRC).

Our goal is to become a leading company in the development of new biotechnological applications based on aptamers.

Aptamer technology is an innovative alternative and much less known than that of monoclonal antibodies. This technology provides multiple applications in biotechnology, health, agriculture-food industry and other sectors.

APTUS activities are focused on:

Aptus facilities are located within the Ramón y Cajal Hospital, Department of Biochemistry-Research.
Highlighted Projects

ApMnk Program

AptusBiotech is developing a therapeutic aptamer against MNK1b (apMNKQ2) that i) inhibits tumorigenesis, affecting proliferation and the ability to form colonies in three breast tumor lines; ii) it produces cell death, mainly through a caspase-mediated apoptotic mechanism; iii) inhibits the metastatic capacity of breast tumor cells, altering the epithelium-mesenchyme transition (TEM) and inhibiting cell migration and invasion. 


After a stroke, cell damage induced by the lack of blood supply causes the release of endogenous cell components to the neuron extracellular medium, triggering central nervous system alarms. One of the primary sensors of these brain damage-associated molecular patterns (DAMPs) is TLR4, a central receptor in innate immunity and expressed on the plasmatic membrane of immune cells such as microglia, neutrophils, monocytes, macrophages, among others.
Latest News